Publication:
First-in-Man Noninvasive Initial Diagnostic Approach of Primary CNS Lymphoma Versus Glioblastoma Using PET with 18F-Fludarabine and l -[methyl-11C]Methionine

Дата
2022
Авторы
Toutain, J.
Pronin, I.
Valable, S.
Gourand, F.
Postnov, A.
Kalaeva, D.
Journal Title
Journal ISSN
Volume Title
Издатель
Научные группы
Организационные подразделения
OrgUnit Logo
Организационная единица
Инженерно-физический институт биомедицины
Цель ИФИБ и стратегия развития – это подготовка высококвалифицированных кадров на базе передовых исследований и разработок новых перспективных методов и материалов в области инженерно-физической биомедицины. Занятие лидерских позиций в биомедицинских технологиях XXI века и внедрение их в образовательный процесс, что отвечает решению практикоориентированной задачи мирового уровня – диагностике и терапии на клеточном уровне социально-значимых заболеваний человека.
Выпуск журнала
Аннотация
© 2022 Wolters Kluwer Health, Inc.Objectives This study sought to assess 18F-fludarabine (18F-FLUDA) PET/CT's ability in differentiating primary central nervous system lymphomas (PCNSLs) from glioblastoma multiformes (GBMs). Patients and Methods Patients harboring either PCNSL (n = 8) before any treatment, PCNSL treated using corticosteroids (PCNSLh; n = 10), or GBM (n = 13) were investigated with conventional MRI and PET/CT, using 11C-MET and 18F-FLUDA. The main parameters measured with each tracer were SUVT and T/N ratios for the first 30 minutes of 11C-MET acquisition, as well as at 3 different times after 18F-FLUDA injection. The early 18F-FLUDA uptake within the first minute of injection was equally considered, whereas this parameter was combined with the later uptakes to obtain R FLUDA 2 and R FLUDA 3 ratios. Results No significant differences in 11C-MET uptakes were observed among PCNSL, PCNSLh, and GBM. With 18F-FLUDA, a clear difference in dynamic GBM uptake was observed, which decreased over time after an early maximum, as compared with that of PCNSL, which steadily increased over time, PCNSLh exhibiting intermediate values. The most discriminative parameters consisting of R FLUDA 2 and R FLUDA 3 integrated the early tracer uptake (first 60 seconds), thereby provided 100% specificity and sensitivity. Conclusions 18F-FLUDA was shown to likely be a promising radiopharmaceutical for differentiating PCNSL from other malignancies, although a pretreatment with corticosteroids might compromise this differential diagnostic ability. The diagnostic role of 18F-FLUDA should be further investigating, along with its potential of defining therapeutic strategies in patients with PCNSL, while assessing the treatments' effectiveness.
Описание
Ключевые слова
Цитирование
First-in-Man Noninvasive Initial Diagnostic Approach of Primary CNS Lymphoma Versus Glioblastoma Using PET with 18F-Fludarabine and l -[methyl-11C]Methionine / Toutain, J. [et al.] // Clinical Nuclear Medicine. - 2022. - 47. - № 8. - P. 699-706. - 10.1097/RLU.0000000000004238
URI
https://www.doi.org/10.1097/RLU.0000000000004238
 https://www.scopus.com/record/display.uri?eid=2-s2.0-85134203457&origin=resultslist
 http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=Alerting&SrcApp=Alerting&DestApp=WOS_CPL&DestLinkType=FullRecord&UT=WOS:000821613800019
 https://openrepository.mephi.ru/handle/123456789/28094
Коллекции
Публикации